Risk adjusted net present value: What is the current valuation of Daiichi Sankyo’s Raludotatug Deruxtecan?
Risk adjusted net present value: What is the current valuation of Daiichi Sankyo’s Raludotatug Deruxtecan?
Raludotatug Deruxtecan is a monoclonal antibody conjugated commercialized by , with a leading Phase I program in Renal Cell Carcinoma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. Smarter leaders trust GlobalData The revenue for Raludotatug Deruxtecan is expected to reach an annual total of $14 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Raludotatug Deruxtecan Overview Raludotatug deruxtecan (DS-6000) is under development for the treatment of ovarian and renal cell carcinoma. It is a monoclonal antibody drug conjugate (ADC) comprises of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker It acts by targeting tumor cells expressing cadherin 6 (CDH6) and acts as topoisomerase I inhibitor. It is administered through intravenous route. Daiichi Sankyo Overview is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. is headquartered in Tokyo, Japan. The company reported revenues of (Yen) JPY1,278,478 million for the fiscal year ended March 2023 (FY2023), an increase of 22.4% over FY2022. In FY2023, the company’s operating margin was 9.3%, compared to an operating margin of 7.1% in FY2022. In FY2023, the company recorded a net margin of 8.5%, compared to a net margin of 6.4% in FY2022. The company reported revenues of JPY350,835 million for the first quarter ended June 2023, an increase of 6.2% over the previous quarter. For a complete picture of Raludotatug Deruxtecan’s valuation, This content was updated on 15 September 2023 Give your business an edge with our leading industry insights. From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company. The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s . Smarter leaders trust GlobalData The gold standard of business intelligence.
Publish Date : 2023-10-04 01:27:23
Image and News Source : pharmaceutical_technology